^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network
Published date:
09/05/2022
Excerpt:
Among the 53 BRAF mutated pts, 21 (40%) received BRAF inhibitors: 17 Dabrafenib + Trametinib (8 as 1st line and 9 post chemotherapy (CT) with a median OS of 14.21 months (4.66-NA) and a median 1L-PFS of 6.38 months (1.79-NA), 4 were treated with Vemurafenib (1 as 1L and 3 post-CT, median OS: 14.91 months (6.88-NA)....These results confirm the clinical benefit of BRAF inhibitors in BRAF mutated ATC in a real-life population.
Source:
Title:
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Published date:
09/13/2021
Excerpt:
Two pts with BRAF mutated ATC received treatment with dabrafenib + trametinib, reaching an ORR of 100% and median PFS of 10 months. Five pts with RET mutated medullary thyroid cancer were treated with a selective RET inhibitor, achieving an ORR of 80%....Targeted therapy resulted in outstanding response rates and may have a significant survival benefit in aggressive tumors, such as ATC.
